2024 Tandem Meetings
ASTCT™ and CIBMTR® look forward to connecting with our international community of healthcare professionals at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® ,
ASTCT™ and CIBMTR® look forward to connecting with our international community of healthcare professionals at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® ,
Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
The findings of this cohort study suggest that approximately two-thirds of patients with aUC did not receive second-line treatment. Most first-line treatments do not include…
Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.
Although scientific progress in HSCT is ongoing, gaps remain in both access to care and outcomes. An Education Session will review the latest research on…
No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.
Wolters Kluwer (“we” or “us”) wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain…
David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.